<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773747</url>
  </required_header>
  <id_info>
    <org_study_id>0683-088</org_study_id>
    <secondary_id>2008_525</secondary_id>
    <nct_id>NCT00773747</nct_id>
  </id_info>
  <brief_title>Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)</brief_title>
  <official_title>An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the efficacy and safety of bortezomib administered in combination with vorinostat in
      patients with relapsed or refractory multiple myeloma. Histone deacetylases (HDAC) facilitate
      gene transcription by modulating the uncoiling of chromatin. HDAC function is dysregulated in
      hematologic and solid malignancies, and this dysregulation may result in over-expression of
      oncogenes. Thus, inhibition of HDACs may result in anti-cancer effects. HDAC inhibitors, like
      vorinostat, represent a new class of antitumor agents that have the ability to induce
      antiproliferative effects including cyto-differentiation, cell cycle growth arrest or
      apoptosis in various cancer cell lines. Several studies have investigated the in vitro
      antimyeloma activity of vorinostat in combination with bortezomib and have demonstrated that
      vorinostat may act synergistically with bortezomib to modulate tumor cell growth. Mitsiades
      et al have shown that vorinostat enhances the sensitivity of bortezomib. Pei et al found that
      exposure of human multiple myeloma cell lines &amp; patient-derived multiple myeloma cells to
      bortezomib and vorinostat resulted in synergistic interactions as a result of: (1)
      Interruption of NF-kB &amp; related signaling pathways (JNK, XIAP, Mcl-1, etc.) (2) Inhibition of
      Hsp90 (3)Induction of ER stress signal and (4) acetylation of Dynein/disruption of aggresome
      function/formation, salvage for ubiquitinated proteins. In addition a marked increase in
      mitochondrial injury, caspase activation, and apoptosis was also observed. Bortezomib is
      indicated for the treatment of patients with multiple myeloma. Two Phase I dose-ranging
      studies of a regimen combining vorinostat and bortezomib among patients with relapsed as well
      asend-stage, refractory multiple myeloma have been conducted. These studies enrolled a total
      of 57 patients. In these studies, administration of vorinostat with standard doses of
      bortezomib resulted in responses in 20/45 (44%) evaluable patients (Weber et al 2007, Badros
      et al 2007). The purpose of the present study is to definitively evaluate the clinical
      activity of vorinostat in combination with bortezomib inpatients with multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of progression-free survival (PFS) in participants treated with vorinostat + bortezomib versus placebo + bortezomib</measure>
    <time_frame>From randomization to event of disease progression or death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical and laboratory adverse events (AEs).</measure>
    <time_frame>From first dose to 30 days after last dose of study drugs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to up to 2 years post last dose in participants treated with vorinostat + bortezomib versus placebo + bortezomib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (TTP) in participants treated with vorinostat + bortezomib versus placebo + bortezomib</measure>
    <time_frame>Every 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) in participants treated with vorinostat + bortezomib versus placebo + bortezomib</measure>
    <time_frame>Every 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">637</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Vorinostat + bortezomib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + bortezomib arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Four 100 mg capsules vorinostat taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.</description>
    <arm_group_label>Vorinostat + bortezomib arm</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.</description>
    <arm_group_label>Vorinostat + bortezomib arm</arm_group_label>
    <arm_group_label>Placebo + bortezomib arm</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to vorinostat</intervention_name>
    <description>Four placebo capsules taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.</description>
    <arm_group_label>Placebo + bortezomib arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Participant has an established diagnosis of multiple myeloma based on the myeloma
             diagnostic criteria.

          -  Participant has received at least 1 but not more than 3 prior anti-myeloma regimens
             and has progressive disease after the most recent treatment regimen.

          -  Participant must have adequate organ function.

        Exclusion criteria:

          -  Participant has had a prior allogeneic bone marrow transplant or plans to undergo any
             type of bone marrow transplantation within 4 weeks of the initiation of study therapy.

          -  Participant has known hypersensitivity to any components of bortezomib or vorinostat.

          -  Participant has active Hepatitis B or C, plasma cell leukemia, or is human
             immunodeficiency virus (HIV) positive.

          -  Participant has had prior treatment with vorinostat or histone deacetylase (HDAC)
             inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19.</citation>
    <PMID>24055414</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms, Plasma Cell</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Hemostatic Disorders</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Paraproteinemias</keyword>
  <keyword>Blood Protein Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Analgesics, Non-Narcotic</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Sensory System Agents</keyword>
  <keyword>Peripheral Nervous System Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Antirheumatic Agents</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Anticarcinogenic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Peripheral Nervous System Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

